Vertex Pharma (VRTX) Tops Q2 EPS by 3c; Reiterates Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $510.08 +1.36%
Revenue Growth %: +10.7%
Financial Fact:
Research and development expenses: 272.37M
Today's EPS Names:
HOVR, VFS, PGR, More
Revenue Growth %: +10.7%
Financial Fact:
Research and development expenses: 272.37M
Today's EPS Names:
HOVR, VFS, PGR, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $0.24, $0.03 better than the analyst estimate of $0.21. Revenue for the quarter came in at $426 million versus the consensus estimate of $427.94 million.
Vertex reiterates 2016 guidance for ORKAMBI product revenues of $1.0 to $1.1 billion and KALYDECO product revenues of $685 to $705 million-
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Misses Q3 EPS by 20c, Beats on Revenue; Cuts FY EPS Guidance
- JPMorgan Starts Woodside Energy Group Ltd (WDS:AU) (WDS) at Neutral
- New Horizon Aircraft (HOVR) Misses Q1 EPS by 6c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
